Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1602 in Participants With Advanced Solid Tumors

NCT03734913 is registered in ClinicalTrials.gov with Guangdong Zhongsheng Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03734913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03734913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1602 in Participants With Advanced Solid Tumors
Lead sponsor
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
January 25, 2019
Completion date
July 31, 2021
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of esophagogastric junction, basal cell carcinoma, glioblastoma, medulloblastoma, neuroendocrine neoplasm, small cell lung cancer